Ontology highlight
ABSTRACT:
SUBMITTER: Schettini F
PROVIDER: S-EPMC7782714 | biostudies-literature | 2021 Jan
REPOSITORIES: biostudies-literature
Schettini Francesco F Chic Nuria N Brasó-Maristany Fara F Paré Laia L Pascual Tomás T Conte Benedetta B Martínez-Sáez Olga O Adamo Barbara B Vidal Maria M Barnadas Esther E Fernández-Martinez Aranzazu A González-Farre Blanca B Sanfeliu Esther E Cejalvo Juan Miguel JM Perrone Giuseppe G Sabarese Giovanna G Zalfa Francesca F Peg Vicente V Fasani Roberta R Villagrasa Patricia P Gavilá Joaquín J Barrios Carlos H CH Lluch Ana A Martín Miguel M Locci Mariavittoria M De Placido Sabino S Prat Aleix A
NPJ breast cancer 20210104 1
Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than ...[more]